Clinical trial · Interventional
Radioimmunoimaging of AL Amyloidosis
Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4
NCT01409148CI-TRIAL-00008257completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AL Amyloidosis | AL Amyloidosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 124I-labeled monoclonal antibody Mu 11-1F4 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- I-124 Mu 11-1F4 sterile injection
- description
- Single arm study
- interventionNames
- Biological: 124I-labeled monoclonal antibody Mu 11-1F4
Primary outcomes (1)
- measure
- Radioimmunoimaging of AL amyloid deposits
- timeFrame
- 36 months
Secondary outcomes (1)
- measure
- Imaging of amyloid deposits as determined by PET/CT
- timeFrame
- 10-14 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of AL Amyloidosis Exclusion Criteria: * New York Heart Association class IV * patient on renal dialysis * serum antibodies to mouse protein
References
Publications (0)
Data not yet available
No reference posted for this study.